# A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.

> **NCT00269971** · PHASE3 · WITHDRAWN · sponsor: **Janssen-Ortho Inc., Canada**

## Conditions studied

- Anemia
- Blood Transfusion
- Orthopedic Surgery

## Interventions

- **DRUG:** epoetin alfa

## Key facts

- **NCT ID:** NCT00269971
- **Lead sponsor:** Janssen-Ortho Inc., Canada
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 1996-05
- **Primary completion:** —
- **Final completion:** 1999-04
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00269971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00269971, "A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00269971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*